Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2008 Mar 28:8:82.
doi: 10.1186/1471-2407-8-82.

Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer

Volker Heinemann  1 , Stefan Boeck, Axel Hinke, Roberto Labianca, Christophe Louvet
Affiliations
Meta-Analysis

Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer

Volker Heinemann et al. BMC Cancer. .

Abstract

Background: Single-agent gemcitabine (GEM) is a standard treatment for advanced and metastatic pancreatic cancer. This study examines the question whether GEM-based combination chemotherapy can further improve treatment efficacy.

Methods: A meta-analysis was performed to evaluate randomized trials comparing GEM versus GEM+X (X = cytotoxic agent). Fifteen trials including 4465 patients were eligible for an analysis of overall survival, the primary end-point of this investigation.

Results: The meta-analysis revealed a significant survival benefit for GEM+X with a pooled hazard ratio (HR) of 0.91 (95% CI: 0.85 - 0.97, p = 0.004). The overall test for heterogeneity resulted in p = 0.82 (I2 = 0%). The analysis of platinum-based combinations indicated a HR of 0.85 (95% CI: 0.76 - 0.96, p = 0.010), while for fluoropyrimidine-based combinations the HR was 0.90 (95% CI: 0.81 - 0.99, p = 0.030). No risk reduction was observed in the group of trials combining GEM with irinotecan, exatecan or pemetrexed (HR = 0.99). A meta-analysis of the trials with adequate information on baseline performance status (PS) was performed in five trials with 1682 patients. This analysis indicated that patients with a good PS had a marked survival benefit when receiving combination chemotherapy (HR = 0.76; 95% CI: 0.67 - 0.87; p < 0.0001). By contrast, application of combination chemotherapy to patients with an initially poor PS appeared to be ineffective (HR = 1.08; 95% CI: 0.90 - 1.29, p = 0.40).

Conclusion: The meta-analysis of randomized trials indicated a significant survival benefit when GEM was either combined with platinum analogs or fluoropyrimidines. Based on a preliminary subgroup analysis (representing 38% of all patients included in this meta-analysis), pancreatic cancer patients with a good PS appear to benefit from GEM-based cytotoxic combinations, whereas patients with a poor PS seem to have no survival benefit from combination chemotherapy.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Meta-analysis for combination chemotherapy in advanced pancreatic cancer – overall survival with regard to combination partner (platinum analog, fluoropyrimidine or other) for gemcitabine.
Figure 2
Figure 2
Meta-analysis for combination chemotherapy in advanced pancreatic cancer – overall survival with regard to performance status.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Evans DB, Abbruzzese JL, Willett CG. Cancer of the pancreas. In: De Vita VT Jr, Hellman S, Rosenberg SA, editor. Cancer: Principles and Practice of Oncology. 6. Philadelphia, PA, Lippincott Williams and Wilkins; 2001. pp. 1126–1161.
    1. Rosewicz S, Wiedenmann B. Pancreatic carcinoma. Lancet. 1997;349:485–489. doi: 10.1016/S0140-6736(96)05523-7. - DOI - PubMed
    1. Louvet C, Labianca R, Hammel P, Lledo G, Zampino MG, André T, Zaniboni A, Ducreux M, Aitini E, Taieb J, Faroux R, Lepere C, de Gramont A. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol. 2005;23:3509–3516. doi: 10.1200/JCO.2005.06.023. - DOI - PubMed
    1. Poplin E, Levy DE, Berlin J, Rothenberg M, Cella D, Mitchell E, Alberts S, Benson A., III Phase III trial of gemcitabine (30-minute infusion) versus gemcitabine (fixed-dose rate-infusion [FDR]) versus gemcitabine+oxaliplatin (GEMOX) in patients with advanced pancreatic cancer (E6201) J Clin Oncol. 2006;24 abstract LBA4004. - PMC - PubMed
    1. Heinemann V, Quietzsch D, Gieseler F, Gonnermann M, Schoenekaes H, Rost A, Neuhaus H, Haag C, Clemens M, Heinrich B, Vehling-Kaiser U, Fuchs M, Fleckenstein D, Gesierich W, Uthgenannt D, Einsele H, Holstege A, Hinke A, Schalhorn A, Wilkowski R. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol. 2006;24:3946–3952. doi: 10.1200/JCO.2005.05.1490. - DOI - PubMed

MeSH terms